Flex Pharma Inc  

(Public, NASDAQ:FLKS)   Watch this stock  
Find more results for ELIZABETH HAHN´┐Ż
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 12.55 - 24.82
Open     -
Vol / Avg. 0.00/78,299.00
Mkt cap 323.90M
P/E     -
Div/yield     -
EPS -5.09
Shares 17.93M
Beta     -
Inst. own 44%
May 6, 2015
Q1 2015 Flex Pharma Inc Earnings Release
May 6, 2015
Q1 2015 Flex Pharma Inc Earnings Call - Webcast
Mar 17, 2015
Q4 2014 Flex Pharma Inc Earnings Release
Mar 17, 2015
Q4 2014 Flex Pharma Inc Earnings Call - Webcast
Mar 12, 2015
Flex Pharma Inc at Barclays Healthcare Conference - Webcast
Mar 10, 2015
Flex Pharma Inc at ROTH Conference - Webcast
Mar 4, 2015
Flex Pharma Inc at Cowen Health Care Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -32.72% -
Return on average equity -46.62% -
Employees 19 -
CDP Score - -


800 Boylston St Fl 24
BOSTON, MA 02199-8119
United States - Map
+1-617-8741821 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Flex Pharma, Inc. (Flex Pharma) is a biotechnology company. The Company is engaged in developing and commercializing products for nocturnal leg cramps, spasms associated with neuromuscular conditions and exercise associated muscle cramps. The Company focuses on its drug development efforts on developing a product to treat nocturnal leg cramps. It develops products based on the mechanism of muscle cramp and spasm inhibition. Flex Pharma’s treatment contains three active ingredients: ginger extract, an activator of both TRPV1 and TRPA1 ion channels; cinnamon extract, an activator of TRPA1 ion channels, and capsicum, an activator of TRPV1 ion channels. The Company is also developing a consumer brand with products based on the same mechanism of action as its treatment. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma's treatment has shown a reduction in the intensity of muscle cramps.

Officers and directors

Christoph H. Westphal Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 46
Bio & Compensation  - Reuters
Marina Hahn President, Consumer
Age: 57
Bio & Compensation  - Reuters
John McCabe Vice President - Finance, Treasurer
Age: 45
Bio & Compensation  - Reuters
Jennifer Cermak Ph.D. Vice President - Research & Development
Age: 42
Bio & Compensation  - Reuters
Robert Hadfield Ph.D. General Counsel, Secretary
Age: 37
Bio & Compensation  - Reuters
Elizabeth Woo M.D., Ph.D. Senior Vice President, Investor Relations and Corporate Communications
Age: 48
Bio & Compensation  - Reuters
Thomas C. Wessel M.D., Ph.D. Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Jeffrey D. Capello Director
Age: 50
Bio & Compensation  - Reuters
Roderick Mackinnon M.D Director
Age: 59
Bio & Compensation  - Reuters
Peter Barton Hutt Non-Executive Independent Director
Age: 80
Bio & Compensation  - Reuters